drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00414 | DB09280 | 590 | 1,604 | [
"DDInter16",
"DDInter1101"
] | Acetohexamide | Lumacaftor | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
590,
24,
1604
]
],
[
[
590,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
590,
24,
1171
],
[
1171,
24,
1604
]
],
[
[
590,
24,
192
],
[
192,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB00073 | DB00446 | 1,394 | 597 | [
"DDInter1608",
"DDInter351"
] | Rituximab | Chloramphenicol | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
1394,
24,
597
]
],
[
[
1394,
24,
599
],
[
599,
24,
597
]
],
[
[
1394,
24,
810
],
[
810,
63,
597
]
],
[
[
1394,
25,
980
],
[
980,
... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Strontium chlori... |
DB01021 | DB09038 | 674 | 1,450 | [
"DDInter1861",
"DDInter636"
] | Trichlormethiazide | Empagliflozin | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
674,
24,
1450
]
],
[
[
674,
24,
659
],
[
659,
63,
1450
]
],
[
[
674,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
674,
24,
885
],
[
885,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanter... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Tr... |
DB01087 | DB09078 | 1,520 | 1,228 | [
"DDInter1520",
"DDInter1036"
] | Primaquine | Lenvatinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1520,
24,
1228
]
],
[
[
1520,
62,
112
],
[
112,
23,
1228
]
],
[
[
1520,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
1520,
24,
938
],
[
938,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Ven... |
DB00407 | DB06209 | 202 | 256 | [
"DDInter115",
"DDInter1508"
] | Ardeparin | Prasugrel | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
202,
25,
256
]
],
[
[
202,
21,
28681
],
[
28681,
60,
256
]
],
[
[
202,
63,
305
],
[
305,
24,
256
]
],
[
[
202,
25,
1479
],
[
1479,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Ardeparin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused b... | Ardeparin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that ... |
DB01004 | DB08889 | 563 | 350 | [
"DDInter806",
"DDInter299"
] | Ganciclovir | Carfilzomib | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
563,
24,
350
]
],
[
[
563,
21,
28762
],
[
28762,
60,
350
]
],
[
[
563,
63,
482
],
[
482,
24,
350
]
],
[
[
563,
24,
310
],
[
310,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Ganciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cau... | Ganciclovir (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfil... |
DB00353 | DB08881 | 588 | 868 | [
"DDInter1187",
"DDInter1925"
] | Methylergometrine | Vemurafenib | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
588,
24,
868
]
],
[
[
588,
6,
8374
],
[
8374,
45,
868
]
],
[
[
588,
7,
19625
],
[
19625,
46,
868
]
],
[
[
588,
18,
8386
],
[
8386,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {... | Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Methylergometrine (Compound) upregulates CCDC92 (Gene) and CCDC92 (Gene) is upregulated by Vemurafenib (Compound)
Methylergometrine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib... |
DB00095 | DB00688 | 66 | 955 | [
"DDInter623",
"DDInter1251"
] | Efalizumab | Mycophenolate mofetil | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Moderate | 1 | [
[
[
66,
24,
955
]
],
[
[
66,
24,
1096
],
[
1096,
40,
955
]
],
[
[
66,
23,
1114
],
[
1114,
62,
955
]
],
[
[
66,
63,
1184
],
[
1184,
2... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic aci... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a mino... |
DB01224 | DB06691 | 623 | 849 | [
"DDInter1553",
"DDInter1155"
] | Quetiapine | Mepyramine | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
623,
24,
849
]
],
[
[
623,
63,
1594
],
[
1594,
24,
849
]
],
[
[
623,
6,
12523
],
[
12523,
45,
849
]
],
[
[
623,
24,
1116
],
[
1116,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Quetiapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Quetiapine may cau... |
DB00026 | DB00552 | 1,184 | 1,238 | [
"DDInter94",
"DDInter1425"
] | Anakinra | Pentostatin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Moderate | 1 | [
[
[
1184,
24,
1238
]
],
[
[
1184,
24,
1083
],
[
1083,
40,
1238
]
],
[
[
1184,
24,
1426
],
[
1426,
1,
1238
]
],
[
[
1184,
24,
1648
],
[
164... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) resembles Pentostatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Pentostatin (Compou... |
DB00563 | DB09156 | 663 | 777 | [
"DDInter1174",
"DDInter964"
] | Methotrexate | Iopromide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
663,
25,
777
]
],
[
[
663,
63,
1648
],
[
1648,
24,
777
]
],
[
[
663,
24,
674
],
[
674,
24,
777
]
],
[
[
663,
24,
242
],
[
242,
6... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesl... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazi... |
DB00446 | DB00631 | 597 | 372 | [
"DDInter351",
"DDInter405"
] | Chloramphenicol | Clofarabine | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
597,
24,
372
]
],
[
[
597,
24,
1426
],
[
1426,
40,
372
]
],
[
[
597,
64,
1064
],
[
1064,
25,
372
]
],
[
[
597,
7,
14278
],
[
14278,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Clofarabine (Compound)
Chloramphenicol may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interact... |
DB00213 | DB01112 | 837 | 665 | [
"DDInter1388",
"DDInter335"
] | Pantoprazole | Cefuroxime | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Moderate | 1 | [
[
[
837,
24,
665
]
],
[
[
837,
24,
1462
],
[
1462,
1,
665
]
],
[
[
837,
21,
28784
],
[
28784,
60,
665
]
],
[
[
837,
24,
1448
],
[
1448,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefuroxime (Compound)
Pantoprazole (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Cefuroxime (Compound)
Pantoprazole may cause a m... |
DB00861 | DB08938 | 914 | 1,384 | [
"DDInter551",
"DDInter1112"
] | Diflunisal | Magaldrate | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
914,
23,
1384
]
],
[
[
914,
63,
167
],
[
167,
23,
1384
]
],
[
[
914,
24,
1220
],
[
1220,
23,
1384
]
],
[
[
914,
25,
1468
],
[
1468,
... | [
[
[
"Diflunisal",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone a... |
DB00792 | DB14575 | 832 | 733 | [
"DDInter1878",
"DDInter674"
] | Tripelennamine | Eslicarbazepine | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
832,
24,
733
]
],
[
[
832,
24,
1264
],
[
1264,
24,
733
]
],
[
[
832,
35,
272
],
[
272,
24,
733
]
],
[
[
832,
63,
1614
],
[
1614,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate inter... |
DB01059 | DB06723 | 956 | 115 | [
"DDInter1313",
"DDInter58"
] | Norfloxacin | Aluminum hydroxide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
956,
24,
115
]
],
[
[
956,
21,
28845
],
[
28845,
60,
115
]
],
[
[
956,
64,
870
],
[
870,
23,
115
]
],
[
[
956,
63,
355
],
[
355,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Norfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is ... | Norfloxacin (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Norfloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum h... |
DB00341 | DB00347 | 1,242 | 917 | [
"DDInter343",
"DDInter1871"
] | Cetirizine | Trimethadione | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Moderate | 1 | [
[
[
1242,
24,
917
]
],
[
[
1242,
21,
28769
],
[
28769,
60,
917
]
],
[
[
1242,
24,
401
],
[
401,
63,
917
]
],
[
[
1242,
63,
475
],
[
475,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethadione"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Sid... | Cetirizine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Trimethadione (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases wh... |
DB00959 | DB01432 | 1,486 | 857 | [
"DDInter1191",
"DDInter368"
] | Methylprednisolone | Cholestyramine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Moderate | 1 | [
[
[
1486,
24,
857
]
],
[
[
1486,
63,
1512
],
[
1512,
23,
857
]
],
[
[
1486,
24,
1411
],
[
1411,
24,
857
]
],
[
[
1486,
40,
870
],
[
870,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofe... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tol... |
DB00807 | DB01087 | 1,120 | 1,520 | [
"DDInter1536",
"DDInter1520"
] | Proparacaine (ophthalmic) | Primaquine | Proparacaine is a benzoate ester. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
1120,
24,
1520
]
],
[
[
1120,
63,
1424
],
[
1424,
24,
1520
]
],
[
[
1120,
1,
1401
],
[
1401,
25,
1520
]
],
[
[
1120,
1,
33
],
[
33,
... | [
[
[
"Proparacaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Proparacaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
... | Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Proparacaine... |
DB01142 | DB01452 | 1,264 | 993 | [
"DDInter593",
"DDInter532"
] | Doxepin | Diamorphine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
1264,
24,
993
]
],
[
[
1264,
63,
421
],
[
421,
40,
993
]
],
[
[
1264,
63,
475
],
[
475,
25,
993
]
],
[
[
1264,
25,
22
],
[
22,
2... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interacti... |
DB00559 | DB06210 | 152 | 72 | [
"DDInter223",
"DDInter631"
] | Bosentan | Eltrombopag | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
152,
24,
72
]
],
[
[
152,
24,
384
],
[
384,
63,
72
]
],
[
[
152,
24,
467
],
[
467,
24,
72
]
],
[
[
152,
25,
124
],
[
124,
63,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvasta... |
DB01075 | DB01233 | 1,376 | 1,311 | [
"DDInter569",
"DDInter1197"
] | Diphenhydramine | Metoclopramide | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1376,
24,
1311
]
],
[
[
1376,
63,
1401
],
[
1401,
24,
1311
]
],
[
[
1376,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
1376,
21,
28691
],
[
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Diphenhydramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compou... |
DB04953 | DB11986 | 495 | 484 | [
"DDInter708",
"DDInter648"
] | Ezogabine | Entrectinib | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
495,
24,
484
]
],
[
[
495,
62,
112
],
[
112,
23,
484
]
],
[
[
495,
23,
1135
],
[
1135,
23,
484
]
],
[
[
495,
63,
222
],
[
222,
2... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxego... |
DB00065 | DB11714 | 581 | 1,316 | [
"DDInter923",
"DDInter610"
] | Infliximab | Durvalumab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Major | 2 | [
[
[
581,
25,
1316
]
],
[
[
581,
23,
1461
],
[
1461,
23,
1316
]
],
[
[
581,
25,
167
],
[
167,
24,
1316
]
],
[
[
581,
24,
1136
],
[
1136,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Durvalumab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Infliximab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may caus... |
DB00489 | DB08938 | 17 | 1,384 | [
"DDInter1704",
"DDInter1112"
] | Sotalol | Magaldrate | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
17,
23,
1384
]
],
[
[
17,
24,
752
],
[
752,
23,
1384
]
],
[
[
17,
25,
401
],
[
401,
23,
1384
]
],
[
[
17,
1,
88
],
[
88,
23,
... | [
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cim... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Sotalol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a mi... |
DB00713 | DB09268 | 1,138 | 1,662 | [
"DDInter1354",
"DDInter1464"
] | Oxacillin | Picosulfuric acid | An antibiotic similar to [flucloxacillin] used in resistant staphylococci infections. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1138,
24,
1662
]
],
[
[
1138,
63,
597
],
[
597,
24,
1662
]
],
[
[
1138,
40,
319
],
[
319,
24,
1662
]
],
[
[
1138,
1,
514
],
[
514,
... | [
[
[
"Oxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]... | Oxacillin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxacillin (Compound) resembles Amoxicillin (Compound) and Amoxicillin may cause a moderate inter... |
DB01044 | DB09080 | 246 | 144 | [
"DDInter809",
"DDInter1331"
] | Gatifloxacin | Olodaterol | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
246,
24,
144
]
],
[
[
246,
1,
956
],
[
956,
24,
144
]
],
[
[
246,
25,
1011
],
[
1011,
24,
144
]
],
[
[
246,
64,
11
],
[
11,
24,
... | [
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a m... | Gatifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Gatifloxacin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerba... |
DB00581 | DB08864 | 355 | 786 | [
"DDInter1018",
"DDInter1595"
] | Lactulose | Rilpivirine | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
355,
24,
786
]
],
[
[
355,
21,
28750
],
[
28750,
60,
786
]
],
[
[
355,
24,
918
],
[
918,
24,
786
]
],
[
[
355,
24,
823
],
[
823,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u} ... | Lactulose (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Rilpivirine (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate disease... |
DB00969 | DB01035 | 2 | 1,401 | [
"DDInter52",
"DDInter1524"
] | Alosetron | Procainamide | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | A derivative of procaine with less CNS action. | Minor | 0 | [
[
[
2,
23,
1401
]
],
[
[
2,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
2,
24,
412
],
[
412,
63,
1401
]
],
[
[
2,
63,
752
],
[
752,
24,
... | [
[
[
"Alosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procainamide"
]
],
[
[
"Alosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused b... | Alosetron (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Procain... |
DB00352 | DB01320 | 482 | 651 | [
"DDInter1814",
"DDInter783"
] | Tioguanine | Fosphenytoin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
482,
24,
651
]
],
[
[
482,
63,
362
],
[
362,
1,
651
]
],
[
[
482,
24,
998
],
[
998,
1,
651
]
],
[
[
482,
21,
28784
],
[
28784,
6... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Fosphenytoin (... |
DB00211 | DB01156 | 1,290 | 593 | [
"DDInter1213",
"DDInter252"
] | Midodrine | Bupropion | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1290,
24,
593
]
],
[
[
1290,
6,
12523
],
[
12523,
45,
593
]
],
[
[
1290,
21,
28757
],
[
28757,
60,
593
]
],
[
[
1290,
23,
752
],
[
752... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Midodrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bupropion (Compound)
Midodrine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Midodrine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine ... |
DB01611 | DB06663 | 1,487 | 1,154 | [
"DDInter893",
"DDInter1398"
] | Hydroxychloroquine | Pasireotide | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1487,
25,
1154
]
],
[
[
1487,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1487,
63,
112
],
[
112,
23,
1154
]
],
[
[
1487,
62,
1247
],
[
12... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Hydroxychloroquine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Eff... | Hydroxychloroquine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical ... |
DB00252 | DB00514 | 362 | 506 | [
"DDInter1460",
"DDInter527"
] | Phenytoin | Dextromethorphan | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
362,
24,
506
]
],
[
[
362,
6,
8374
],
[
8374,
45,
506
]
],
[
[
362,
18,
5901
],
[
5901,
57,
506
]
],
[
[
362,
21,
28929
],
[
28929,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextromethorphan (Compound)
Phenytoin (Compound) downregulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Dextromethorphan (Compound)
Phenytoin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by D... |
DB00196 | DB00687 | 600 | 870 | [
"DDInter743",
"DDInter747"
] | Fluconazole | Fludrocortisone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
600,
24,
870
]
],
[
[
600,
24,
1220
],
[
1220,
40,
870
]
],
[
[
600,
24,
1561
],
[
1561,
24,
870
]
],
[
[
600,
21,
28936
],
[
28936,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone may cause a moderate inter... |
DB00563 | DB00749 | 663 | 59 | [
"DDInter1174",
"DDInter699"
] | Methotrexate | Etodolac | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Major | 2 | [
[
[
663,
25,
59
]
],
[
[
663,
7,
7720
],
[
7720,
45,
59
]
],
[
[
663,
6,
1829
],
[
1829,
45,
59
]
],
[
[
663,
21,
28897
],
[
28897,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etodolac"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"E... | Methotrexate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etodolac (Compound)
Methotrexate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Etodolac (Compound)
Methotrexate (Compound) causes Coma (Side Effect) and Coma (Side Effect) is caused by Etodolac (Compound)
Methotrexate may cause a mod... |
DB00382 | DB00969 | 62 | 2 | [
"DDInter1734",
"DDInter52"
] | Tacrine | Alosetron | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Moderate | 1 | [
[
[
62,
24,
2
]
],
[
[
62,
24,
1362
],
[
1362,
63,
2
]
],
[
[
62,
25,
1510
],
[
1510,
63,
2
]
],
[
[
62,
24,
752
],
[
752,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olap... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Alosetron
Tacrine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a mod... |
DB08870 | DB15965 | 850 | 1,330 | [
"DDInter228",
"DDInter1270"
] | Brentuximab vedotin | Naxitamab | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
850,
24,
1330
]
],
[
[
850,
63,
14
],
[
14,
24,
1330
]
],
[
[
850,
24,
350
],
[
350,
24,
1330
]
],
[
[
850,
64,
329
],
[
329,
24... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastat... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00800 | DB01069 | 572 | 401 | [
"DDInter720",
"DDInter1533"
] | Fenoldopam | Promethazine | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
572,
24,
401
]
],
[
[
572,
24,
1264
],
[
1264,
63,
401
]
],
[
[
572,
24,
104
],
[
104,
24,
401
]
],
[
[
572,
6,
5214
],
[
5214,
... | [
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00047 | DB01579 | 176 | 341 | [
"DDInter932",
"DDInter1439"
] | Insulin glargine | Phendimetrazine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
176,
24,
341
]
],
[
[
176,
24,
959
],
[
959,
24,
341
]
],
[
[
176,
24,
1281
],
[
1281,
63,
341
]
],
[
[
176,
24,
121
],
[
121,
2... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Linagl... |
DB00575 | DB01156 | 1,020 | 593 | [
"DDInter412",
"DDInter252"
] | Clonidine | Bupropion | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1020,
24,
593
]
],
[
[
1020,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1020,
10,
11601
],
[
11601,
49,
593
]
],
[
[
1020,
21,
29491
],
[
294... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Clonidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clonidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Clonidine (Compound) palliates attention deficit hyperactivity disorder (Disease) and attention deficit hyperactivity disorder (Disease) is palliated by Bupropion (Compound)
Clonidine (Compound) causes Dental caries (Side Effect... |
DB04865 | DB11166 | 4 | 18 | [
"DDInter1335",
"DDInter104"
] | Omacetaxine mepesuccinate | Antithrombin Alfa | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Major | 2 | [
[
[
4,
25,
18
]
],
[
[
4,
64,
714
],
[
714,
24,
18
]
],
[
[
4,
24,
738
],
[
738,
63,
18
]
],
[
[
4,
25,
578
],
[
578,
24,
18
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
... | Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Nir... |
DB01232 | DB11718 | 1,327 | 927 | [
"DDInter1640",
"DDInter640"
] | Saquinavir | Encorafenib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1327,
25,
927
]
],
[
[
1327,
62,
112
],
[
112,
23,
927
]
],
[
[
1327,
24,
720
],
[
720,
24,
927
]
],
[
[
1327,
63,
1324
],
[
1324,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Saquinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB00480 | DB08894 | 1,668 | 1,126 | [
"DDInter1035",
"DDInter1406"
] | Lenalidomide | Peginesatide | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of th... | Major | 2 | [
[
[
1668,
25,
1126
]
],
[
[
1668,
25,
1514
],
[
1514,
24,
1126
]
],
[
[
1668,
25,
687
],
[
687,
63,
1126
]
],
[
[
1668,
1,
770
],
[
770,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginesatide"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human C1-esterase inhibitor"
],
[
"Hu... | Lenalidomide may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor and Human C1-esterase inhibitor may cause a moderate interaction that could exacerbate diseases when taken with Peginesatide
Lenalidomide may lead to a major life threatening interaction when taken with Conestat al... |
DB08885 | DB09498 | 363 | 810 | [
"DDInter33",
"DDInter1715"
] | Aflibercept | Strontium chloride Sr-89 | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
363,
24,
810
]
],
[
[
363,
63,
597
],
[
597,
24,
810
]
],
[
[
363,
24,
1362
],
[
1362,
24,
810
]
],
[
[
363,
24,
738
],
[
738,
6... | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphen... | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00994 | DB01416 | 361 | 1,024 | [
"DDInter1277",
"DDInter326"
] | Neomycin | Cefpodoxime | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
361,
24,
1024
]
],
[
[
361,
24,
1453
],
[
1453,
1,
1024
]
],
[
[
361,
63,
149
],
[
149,
40,
1024
]
],
[
[
361,
24,
665
],
[
665,
... | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftriaxone"
],
[
... | Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftriaxone and Ceftriaxone (Compound) resembles Cefpodoxime (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefpodoxime (Compound... |
DB00222 | DB00294 | 245 | 1,336 | [
"DDInter825",
"DDInter701"
] | Glimepiride | Etonogestrel | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Moderate | 1 | [
[
[
245,
24,
1336
]
],
[
[
245,
24,
566
],
[
566,
1,
1336
]
],
[
[
245,
24,
1561
],
[
1561,
40,
1336
]
],
[
[
245,
21,
28900
],
[
28900,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Etonogestrel (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Etonog... |
DB00445 | DB00722 | 322 | 743 | [
"DDInter655",
"DDInter1079"
] | Epirubicin | Lisinopril | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
322,
24,
743
]
],
[
[
322,
24,
610
],
[
610,
40,
743
]
],
[
[
322,
24,
1638
],
[
1638,
1,
743
]
],
[
[
322,
21,
28691
],
[
28691,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisinopril (Compound... |
DB00361 | DB15091 | 134 | 676 | [
"DDInter1939",
"DDInter1901"
] | Vinorelbine | Upadacitinib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
134,
25,
676
]
],
[
[
134,
63,
1461
],
[
1461,
23,
676
]
],
[
[
134,
24,
1430
],
[
1430,
24,
676
]
],
[
[
134,
24,
1654
],
[
1654,
... | [
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipu... |
DB08816 | DB12500 | 578 | 283 | [
"DDInter1802",
"DDInter714"
] | Ticagrelor | Fedratinib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
578,
24,
283
]
],
[
[
578,
23,
271
],
[
271,
23,
283
]
],
[
[
578,
24,
351
],
[
351,
23,
283
]
],
[
[
578,
63,
122
],
[
122,
23,... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib... |
DB00759 | DB08903 | 1,620 | 996 | [
"DDInter1783",
"DDInter170"
] | Tetracycline | Bedaquiline | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
1620,
24,
996
]
],
[
[
1620,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1620,
1,
964
],
[
964,
24,
996
]
],
[
[
1620,
63,
305
],
[
305,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Tetracycline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Tetracycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Tetracycline may cause a moderate interaction that could e... |
DB00662 | DB01589 | 717 | 481 | [
"DDInter1873",
"DDInter1552"
] | Trimethobenzamide | Quazepam | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
717,
24,
481
]
],
[
[
717,
24,
1216
],
[
1216,
1,
481
]
],
[
[
717,
63,
523
],
[
523,
1,
481
]
],
[
[
717,
63,
905
],
[
905,
40,... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Quazepam (... |
DB00241 | DB12015 | 288 | 1,033 | [
"DDInter257",
"DDInter53"
] | Butalbital | Alpelisib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
288,
24,
1033
]
],
[
[
288,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
288,
24,
1344
],
[
1344,
24,
1033
]
],
[
[
288,
1,
536
],
[
536,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canaglif... |
DB00675 | DB09065 | 888 | 760 | [
"DDInter1744",
"DDInter424"
] | Tamoxifen | Cobicistat | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
888,
24,
760
]
],
[
[
888,
24,
479
],
[
479,
23,
760
]
],
[
[
888,
25,
271
],
[
271,
23,
760
]
],
[
[
888,
64,
1230
],
[
1230,
2... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tamoxifen may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a mino... |
DB02701 | DB06655 | 1,632 | 5 | [
"DDInter1289",
"DDInter1077"
] | Nicotinamide | Liraglutide | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1632,
24,
5
]
],
[
[
1632,
63,
245
],
[
245,
24,
5
]
],
[
[
1632,
24,
637
],
[
637,
63,
5
]
],
[
[
1632,
63,
245
],
[
245,
23,
... | [
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase E... |
DB00006 | DB06605 | 942 | 1,409 | [
"DDInter217",
"DDInter108"
] | Bivalirudin | Apixaban | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
942,
25,
1409
]
],
[
[
942,
23,
539
],
[
539,
62,
1409
]
],
[
[
942,
24,
109
],
[
109,
24,
1409
]
],
[
[
942,
24,
41
],
[
41,
63... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may... |
DB06791 | DB15091 | 1,446 | 676 | [
"DDInter1021",
"DDInter1901"
] | Lanreotide | Upadacitinib | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
1446,
24,
676
]
],
[
[
1446,
63,
655
],
[
655,
24,
676
]
],
[
[
1446,
24,
1375
],
[
1375,
24,
676
]
],
[
[
1446,
24,
800
],
[
800,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefam... |
DB01136 | DB09291 | 772 | 741 | [
"DDInter305",
"DDInter1615"
] | Carvedilol | Rolapitant | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
772,
24,
741
]
],
[
[
772,
24,
159
],
[
159,
63,
741
]
],
[
[
772,
24,
973
],
[
973,
24,
741
]
],
[
[
772,
63,
401
],
[
401,
24,... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and ... |
DB00227 | DB06210 | 1,463 | 72 | [
"DDInter1098",
"DDInter631"
] | Lovastatin | Eltrombopag | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
1463,
24,
72
]
],
[
[
1463,
6,
3486
],
[
3486,
45,
72
]
],
[
[
1463,
25,
384
],
[
384,
63,
72
]
],
[
[
1463,
35,
467
],
[
467,
2... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Lovastatin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Eltrombopag (Compound)
Lovastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Lovastatin (Compound) resembles... |
DB04946 | DB12332 | 924 | 1,619 | [
"DDInter907",
"DDInter1626"
] | Iloperidone | Rucaparib | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
924,
25,
1619
]
],
[
[
924,
63,
222
],
[
222,
23,
1619
]
],
[
[
924,
62,
112
],
[
112,
23,
1619
]
],
[
[
924,
24,
1662
],
[
1662,
... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutram... | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metr... |
DB00358 | DB12500 | 1,010 | 283 | [
"DDInter1140",
"DDInter714"
] | Mefloquine | Fedratinib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1010,
24,
283
]
],
[
[
1010,
25,
351
],
[
351,
23,
283
]
],
[
[
1010,
24,
555
],
[
555,
23,
283
]
],
[
[
1010,
24,
1339
],
[
1339,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Mefloquine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a ... |
DB00261 | DB00980 | 702 | 969 | [
"DDInter93",
"DDInter1564"
] | Anagrelide | Ramelteon | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
702,
24,
969
]
],
[
[
702,
6,
7950
],
[
7950,
45,
969
]
],
[
[
702,
21,
28714
],
[
28714,
60,
969
]
],
[
[
702,
25,
1619
],
[
1619,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ramelteon (Compound)
Anagrelide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a mo... |
DB00366 | DB01057 | 1,594 | 1,318 | [
"DDInter600",
"DDInter615"
] | Doxylamine | Echothiophate (ophthalmic) | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Ecothiopate is the phosphorothioate obtained by formal condensation of diethyl phosphate with N,N,N-trimethyl-2-sulfanylethanaminium. An irreversible acetylcholinesterase inhibitor, its iodide salt is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inad... | Moderate | 1 | [
[
[
1594,
24,
1318
]
],
[
[
1594,
21,
29254
],
[
29254,
60,
1318
]
],
[
[
1594,
24,
830
],
[
830,
63,
1318
]
],
[
[
1594,
24,
1219
],
[
12... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Echothiophate"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Lacrimation"
],
[
"Lacrimation",
"{u} (Side Effect) ... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Doxylamine (Compound) causes Lacrimation (Side Effect) and Lacrimation (Side Effect) is caused by Echothiophate (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB00278 | DB10344 | 291 | 992 | [
"DDInter117",
"DDInter818"
] | Argatroban | Ginger | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
291,
24,
992
]
],
[
[
291,
25,
1421
],
[
1421,
63,
992
]
],
[
[
291,
64,
1167
],
[
1167,
24,
992
]
],
[
[
291,
25,
1347
],
[
1347,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
... | Argatroban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Argatroban may lead to a major life threatening interaction when taken with Streptokinase and Streptokinase may cause a moderate in... |
DB00461 | DB00975 | 598 | 1,317 | [
"DDInter1254",
"DDInter573"
] | Nabumetone | Dipyridamole | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
598,
24,
1317
]
],
[
[
598,
18,
2201
],
[
2201,
57,
1317
]
],
[
[
598,
21,
28748
],
[
28748,
60,
1317
]
],
[
[
598,
24,
714
],
[
714,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Nabumetone",
"{u} (Compound) downregulates {v} (Gene)",
"PPP2R5E"
],
[
"PPP2R5E",
"{u} (Gene) is downregulated... | Nabumetone (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Dipyridamole (Compound)
Nabumetone (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Dipyridamole (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB05239 | DB08865 | 866 | 1,593 | [
"DDInter425",
"DDInter448"
] | Cobimetinib | Crizotinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
866,
25,
1593
]
],
[
[
866,
64,
307
],
[
307,
23,
1593
]
],
[
[
866,
25,
283
],
[
283,
62,
1593
]
],
[
[
866,
24,
1627
],
[
1627,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} m... | Cobimetinib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Cobimetinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interacti... |
DB00047 | DB09045 | 176 | 52 | [
"DDInter932",
"DDInter607"
] | Insulin glargine | Dulaglutide | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
176,
24,
52
]
],
[
[
176,
23,
1103
],
[
1103,
23,
52
]
],
[
[
176,
24,
170
],
[
170,
23,
52
]
],
[
[
176,
24,
280
],
[
280,
24,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
... | Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin ... |
DB00087 | DB14444 | 599 | 151 | [
"DDInter41",
"DDInter924"
] | Alemtuzumab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
599,
24,
151
]
],
[
[
599,
24,
66
],
[
66,
24,
151
]
],
[
[
599,
63,
1394
],
[
1394,
24,
151
]
],
[
[
599,
25,
1066
],
[
1066,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Alemtuzumab may cause a moderate int... |
DB00262 | DB00390 | 552 | 1,252 | [
"DDInter302",
"DDInter554"
] | Carmustine | Digoxin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Moderate | 1 | [
[
[
552,
24,
1252
]
],
[
[
552,
21,
28784
],
[
28784,
60,
1252
]
],
[
[
552,
25,
752
],
[
752,
62,
1252
]
],
[
[
552,
25,
976
],
[
976,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Carmustine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effe... | Carmustine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Digoxin (Compound)
Carmustine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Digoxin
Carmu... |
DB00281 | DB12130 | 608 | 1,017 | [
"DDInter1066",
"DDInter1094"
] | Lidocaine | Lorlatinib | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Minor | 0 | [
[
[
608,
23,
1017
]
],
[
[
608,
23,
1101
],
[
1101,
23,
1017
]
],
[
[
608,
24,
976
],
[
976,
24,
1017
]
],
[
[
608,
23,
1322
],
[
1322,
... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"B... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib... |
DB06754 | DB14006 | 707 | 972 | [
"DDInter471",
"DDInter370"
] | Danaparoid | Choline salicylate | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity tha... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
707,
24,
972
]
],
[
[
707,
64,
553
],
[
553,
24,
972
]
],
[
[
707,
63,
222
],
[
222,
24,
972
]
],
[
[
707,
24,
1074
],
[
1074,
2... | [
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"... | Danaparoid may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutram... |
DB00031 | DB01166 | 20 | 477 | [
"DDInter1764",
"DDInter379"
] | Tenecteplase | Cilostazol | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
20,
24,
477
]
],
[
[
20,
23,
297
],
[
297,
62,
477
]
],
[
[
20,
25,
126
],
[
126,
23,
477
]
],
[
[
20,
24,
109
],
[
109,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Tenecteplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor intera... |
DB00250 | DB01097 | 10 | 1,377 | [
"DDInter475",
"DDInter1033"
] | Dapsone | Leflunomide | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Moderate | 1 | [
[
[
10,
24,
1377
]
],
[
[
10,
5,
11653
],
[
11653,
44,
1377
]
],
[
[
10,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
10,
18,
4930
],
[
4930,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Dapsone",
"{u} (Compound) treats {v} (Disease)",
"systemic lupus erythematosus"
],
[
"systemic lupus erythematosus",
... | Dapsone (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Leflunomide (Compound)
Dapsone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Dapsone (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Lefl... |
DB00001 | DB00574 | 1,578 | 121 | [
"DDInter1037",
"DDInter717"
] | Lepirudin | Fenfluramine | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
1578,
24,
121
]
],
[
[
1578,
25,
366
],
[
366,
24,
121
]
],
[
[
1578,
24,
24
],
[
24,
24,
121
]
],
[
[
1578,
24,
958
],
[
958,
6... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifiba... | Lepirudin may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin may cause ... |
DB01041 | DB13074 | 770 | 877 | [
"DDInter1789",
"DDInter1110"
] | Thalidomide | Macimorelin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
770,
24,
877
]
],
[
[
770,
63,
112
],
[
112,
23,
877
]
],
[
[
770,
63,
1020
],
[
1020,
24,
877
]
],
[
[
770,
24,
1191
],
[
1191,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and ... |
DB00556 | DB11730 | 1,262 | 351 | [
"DDInter1429",
"DDInter1588"
] | Perflutren | Ribociclib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1262,
25,
351
]
],
[
[
1262,
23,
112
],
[
112,
23,
351
]
],
[
[
1262,
24,
355
],
[
355,
24,
351
]
],
[
[
1262,
24,
129
],
[
129,
... | [
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Perflutren",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactu... |
DB01105 | DB14881 | 222 | 180 | [
"DDInter1665",
"DDInter1329"
] | Sibutramine | Oliceridine | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
222,
24,
180
]
],
[
[
222,
63,
401
],
[
401,
24,
180
]
],
[
[
222,
24,
649
],
[
649,
24,
180
]
],
[
[
222,
23,
484
],
[
484,
24,... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and... |
DB00963 | DB08875 | 1,263 | 1,618 | [
"DDInter241",
"DDInter262"
] | Bromfenac | Cabozantinib | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1263,
25,
1618
]
],
[
[
1263,
24,
384
],
[
384,
63,
1618
]
],
[
[
1263,
24,
850
],
[
850,
24,
1618
]
],
[
[
1263,
64,
629
],
[
629,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin a... |
DB08868 | DB11703 | 1,011 | 405 | [
"DDInter737",
"DDInter9"
] | Fingolimod | Acalabrutinib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1011,
25,
405
]
],
[
[
1011,
64,
139
],
[
139,
24,
405
]
],
[
[
1011,
25,
951
],
[
951,
24,
405
]
],
[
[
1011,
25,
982
],
[
982,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u... | Fingolimod may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fingolimod may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate... |
DB00220 | DB00743 | 798 | 808 | [
"DDInter1276",
"DDInter792"
] | Nelfinavir | Gadobenic acid | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Moderate | 1 | [
[
[
798,
24,
808
]
],
[
[
798,
21,
28769
],
[
28769,
60,
808
]
],
[
[
798,
1,
215
],
[
215,
24,
808
]
],
[
[
798,
40,
1327
],
[
1327,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Nelfinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Si... | Nelfinavir (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Gadobenic acid (Compound)
Nelfinavir (Compound) resembles Indinavir (Compound) and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Nelfinavir (Compound) re... |
DB00747 | DB04908 | 1,442 | 1,671 | [
"DDInter1647",
"DDInter741"
] | Scopolamine | Flibanserin | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
1442,
24,
1671
]
],
[
[
1442,
24,
830
],
[
830,
24,
1671
]
],
[
[
1442,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
1442,
24,
407
],
[
407,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and... |
DB01403 | DB13074 | 9 | 877 | [
"DDInter1175",
"DDInter1110"
] | Methotrimeprazine | Macimorelin | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
9,
25,
877
]
],
[
[
9,
62,
112
],
[
112,
23,
877
]
],
[
[
9,
63,
85
],
[
85,
24,
877
]
],
[
[
9,
24,
913
],
[
913,
24,
877... | [
[
[
"Methotrimeprazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Atro... |
DB09075 | DB14006 | 498 | 972 | [
"DDInter621",
"DDInter370"
] | Edoxaban | Choline salicylate | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
498,
24,
972
]
],
[
[
498,
64,
553
],
[
553,
24,
972
]
],
[
[
498,
63,
1039
],
[
1039,
24,
972
]
],
[
[
498,
24,
1074
],
[
1074,
... | [
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fond... | Edoxaban may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfl... |
DB00489 | DB11057 | 17 | 720 | [
"DDInter1704",
"DDInter1223"
] | Sotalol | Mineral oil | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
17,
24,
720
]
],
[
[
17,
25,
927
],
[
927,
63,
720
]
],
[
[
17,
25,
1151
],
[
1151,
24,
720
]
],
[
[
17,
64,
79
],
[
79,
24,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
... | Sotalol may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Sotalol may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interacti... |
DB01168 | DB09401 | 1,053 | 928 | [
"DDInter1526",
"DDInter988"
] | Procarbazine | Isosorbide | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the... | Moderate | 1 | [
[
[
1053,
24,
928
]
],
[
[
1053,
24,
820
],
[
820,
24,
928
]
],
[
[
1053,
63,
1061
],
[
1061,
24,
928
]
],
[
[
1053,
64,
290
],
[
290,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isosorbide"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Isosorbide
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil an... |
DB00731 | DB08820 | 1,144 | 1,478 | [
"DDInter1269",
"DDInter997"
] | Nateglinide | Ivacaftor | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1144,
24,
1478
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1144,
21,
28900
],
[
28900,
60,
1478
]
],
[
[
1144,
24,
318
],
[
31... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Nateglinide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Ivacaftor (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Escitalo... |
DB00284 | DB00467 | 1,647 | 1,467 | [
"DDInter11",
"DDInter644"
] | Acarbose | Enoxacin | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Moderate | 1 | [
[
[
1647,
24,
1467
]
],
[
[
1647,
24,
1539
],
[
1539,
40,
1467
]
],
[
[
1647,
24,
1299
],
[
1299,
1,
1467
]
],
[
[
1647,
63,
1176
],
[
117... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Of... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin (Compound) resembles Enoxacin (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Enoxacin (Compound)
Acar... |
DB01045 | DB01132 | 463 | 1,130 | [
"DDInter1590",
"DDInter1472"
] | Rifampicin | Pioglitazone | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
463,
24,
1130
]
],
[
[
463,
6,
6017
],
[
6017,
45,
1130
]
],
[
[
463,
63,
303
],
[
303,
23,
1130
]
],
[
[
463,
64,
11
],
[
11,
2... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Rifampicin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pioglitazone (Compound)
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken ... |
DB00352 | DB01438 | 482 | 585 | [
"DDInter1814",
"DDInter1438"
] | Tioguanine | Phenazopyridine | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during urination. In the USA, this drug was previously marked by Roche but has been discontinued by the FDA. It is still us... | Moderate | 1 | [
[
[
482,
24,
585
]
],
[
[
482,
21,
28658
],
[
28658,
60,
585
]
],
[
[
482,
24,
384
],
[
384,
63,
585
]
],
[
[
482,
24,
372
],
[
372,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenazopyridine"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is c... | Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Phenazopyridine (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Phen... |
DB00353 | DB12332 | 588 | 1,619 | [
"DDInter1187",
"DDInter1626"
] | Methylergometrine | Rucaparib | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
588,
24,
1619
]
],
[
[
588,
24,
1419
],
[
1419,
24,
1619
]
],
[
[
588,
24,
159
],
[
159,
63,
1619
]
],
[
[
588,
1,
1131
],
[
1131,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
... | Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectini... |
DB06228 | DB11791 | 792 | 785 | [
"DDInter1609",
"DDInter287"
] | Rivaroxaban | Capmatinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
792,
24,
785
]
],
[
[
792,
63,
1324
],
[
1324,
24,
785
]
],
[
[
792,
24,
868
],
[
868,
24,
785
]
],
[
[
792,
24,
1320
],
[
1320,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and... |
DB00521 | DB06791 | 493 | 1,446 | [
"DDInter304",
"DDInter1021"
] | Carteolol (ophthalmic) | Lanreotide | Carteolol is a quinolone and a secondary alcohol. It has a role as a beta-adrenergic antagonist, an antihypertensive agent, an antiglaucoma drug, an anti-arrhythmia drug and a sympatholytic agent. It is a conjugate base of a carteolol(1+). | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
493,
24,
1446
]
],
[
[
493,
40,
887
],
[
887,
24,
1446
]
],
[
[
493,
1,
699
],
[
699,
24,
1446
]
],
[
[
493,
40,
887
],
[
887,
2... | [
[
[
"Carteolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Carteolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate inte... | Carteolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Carteolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Carteolol (Compound) resembles Nadolol (Compound) and Nadolol ma... |
DB00022 | DB11642 | 268 | 938 | [
"DDInter1408",
"DDInter1480"
] | Peginterferon alfa-2b | Pitolisant | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
268,
24,
938
]
],
[
[
268,
24,
112
],
[
112,
23,
938
]
],
[
[
268,
24,
322
],
[
322,
24,
938
]
],
[
[
268,
25,
676
],
[
676,
63,... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metro... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00019 | DB01157 | 1,257 | 304 | [
"DDInter1405",
"DDInter1875"
] | Pegfilgrastim | Trimetrexate | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Moderate | 1 | [
[
[
1257,
24,
304
]
],
[
[
1257,
24,
599
],
[
599,
24,
304
]
],
[
[
1257,
24,
384
],
[
384,
63,
304
]
],
[
[
1257,
25,
1064
],
[
1064,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib ... |
DB01359 | DB09134 | 729 | 1,552 | [
"DDInter1417",
"DDInter966"
] | Penbutolol | Ioversol | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Moderate | 1 | [
[
[
729,
24,
1552
]
],
[
[
729,
1,
699
],
[
699,
24,
1552
]
],
[
[
729,
63,
1648
],
[
1648,
24,
1552
]
],
[
[
729,
40,
461
],
[
461,
... | [
[
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate intera... | Penbutolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exace... |
DB06655 | DB06663 | 5 | 1,154 | [
"DDInter1077",
"DDInter1398"
] | Liraglutide | Pasireotide | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
5,
24,
1154
]
],
[
[
5,
63,
966
],
[
966,
40,
1154
]
],
[
[
5,
63,
959
],
[
959,
24,
1154
]
],
[
[
5,
24,
154
],
[
154,
63,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that coul... |
DB00601 | DB12834 | 453 | 148 | [
"DDInter1073",
"DDInter1649"
] | Linezolid | Secnidazole | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
453,
24,
148
]
],
[
[
453,
24,
1593
],
[
1593,
24,
148
]
],
[
[
453,
63,
597
],
[
597,
24,
148
]
],
[
[
453,
25,
1510
],
[
1510,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Ch... |
DB11714 | DB14711 | 1,316 | 779 | [
"DDInter610",
"DDInter1680"
] | Durvalumab | Smallpox (Vaccinia) Vaccine, Live | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1316,
25,
779
]
],
[
[
1316,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1316,
25,
1259
],
[
1259,
25,
779
]
],
[
[
1316,
63,
1220
],
[
1220,... | [
[
[
"Durvalumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Durvalumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cl... | Durvalumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Durvalumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a m... |
DB12159 | DB15091 | 12 | 676 | [
"DDInter609",
"DDInter1901"
] | Dupilumab | Upadacitinib | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
12,
25,
676
]
],
[
[
12,
62,
1193
],
[
1193,
23,
676
]
],
[
[
12,
63,
1430
],
[
1430,
24,
676
]
],
[
[
12,
24,
1129
],
[
1129,
2... | [
[
[
"Dupilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Dupilumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Dupilumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and ... |
DB00060 | DB15066 | 912 | 445 | [
"DDInter947",
"DDInter821"
] | Interferon beta-1a | Givosiran | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
912,
24,
445
]
],
[
[
912,
24,
1555
],
[
1555,
24,
445
]
],
[
[
912,
63,
1560
],
[
1560,
24,
445
]
],
[
[
912,
25,
1377
],
[
1377,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pega... |
DB00196 | DB00731 | 600 | 1,144 | [
"DDInter743",
"DDInter1269"
] | Fluconazole | Nateglinide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
600,
24,
1144
]
],
[
[
600,
6,
6799
],
[
6799,
45,
1144
]
],
[
[
600,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
600,
24,
254
],
[
254,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound... | Fluconazole (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Nateglinide (Compound)
Fluconazole (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone a... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.